Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — H1 2023 Earnings Presentation
31 slides from Telix Pharmaceuticals's earnings presentation, Aug 23, 2023
Slide 1: H1 2023 Results Presentation
H1 2023 Results Presentation Telix Pharmaceuticals (ASX:TLX) 23 August 2023 Illustration of TLX250-CDx binding to carbonic anhydrase IX
Slide 2: Disclaimer
Disclaimer This presentation is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, the United States and the United Kingdom). This presentation contains summary information about Telix Pharmaceuticals Limi
Slide 3: Presenters
Presenters Kyahn Williamson Dr Christian Behrenbruch Dr Colin Hayward Darren Smith SVP Investor Relations Managing Director and Group Chief Medical Group Chief Financial and Corporate Group Chief Executive Officer Officer Communications Officer 3
Slide 4: Delivering on the promise of precision medicine through targeted radiation
Delivering on the promise of precision medicine through targeted radiation Positive ZIRCON Ph III Pipeline and technology readout, delivers on a expansion through major unmet need in acquisitions and in- diagnosis of ccRCC licensing Our journey over the past 12 months Highly successful Multiple tria
Slide 5: Financial highlights
Financial highlights Telix has rapidly transitioned to a sustainable commercial business • Continued strong revenue growth since commercial launch of Illuccix in H1 2022 REVENUE EARNINGS1 • Earnings (Adjusted EBITDAR1) demonstrates the profitability of the Up 820% to $220.8M Up $110.4M to $82.4M com
Slide 6: Delivering to our strategy
Delivering to our strategy Achievements in H1 2023 create a platform for further value creation • Positive growth outlook for Illuccix as PSMA-PET1 imaging market Grow Illuccix revenue globally evolves. Telix has a highly differentiated offering for the urology field Commercialise the • Scale-up und
Slide 7: Financial Commentary
Financial Commentary OTelix —— ae
Slide 8: Sustained growth following Illuccix launch
Sustained growth following Illuccix launch U.S. Illuccix sales continue to deliver growth in H1 2023 • Group revenue up 820% to $220.8M Group revenue (A$M) 250 (H1 2022: $24.0M1), up 62% on H2 2022 220.8 • U.S. revenue from Illuccix the main 200 driver with $213.5M ($US143.8M) recorded during H1 202
Slide 9: Income statement summary
Income statement summary Investing for future growth, while delivering an improvement in earnings • Significant increase in gross profit HALF-YEAR H1 2022 vs H1 2023 H2 2022 vs H1 2023 H1 2022 H2 2022 H1 2023 Var. Var. Var. Var. • H1 2022 included one-off launch costs and three months sales $M $M $M
Slide 10: Growing revenue building a sustainable business
Growing revenue building a sustainable business Key expenditure continues to reduce as a percentage of sales • Gross margin improvement of 8 basis Revenue (A$M) and gross margin percentage (%) points from H1 2022, reflects operating 250 64% 65% 63% expenditure at normalised levels 200 60% • Continue
Slide 11: Improving profitability
Improving profitability H1 2023 builds on strong H2 2022 performance Adjusted EBITDA and Adjusted EBITDAR (A$M) • Telix finishes H1 2023 with profitability 100.0 continuing to improve: 80.0 • Adjusted EBITDA1 improved by $41.7M 60.0 from H2 2022 to $34.7M, which excludes the non-cash contingent cons
Slide 12: Illuccix Commercial Update
Illuccix® Commercial Update
Slide 13: Four major focus areas in 2023
Four major focus areas in 2023 Strong progress across all major value creating catalysts H2 H2 H2 ProstACT New Drug Illuccix® - Biologics License GLOBAL patient Application (NDA) continued revenue Application (BLA) recruitment and for brain cancer growth and global submission for ProstACT imaging ro
Slide 14: Sustained, strong revenue growth in U.S. market
Sustained, strong revenue growth in U.S. market Illuccix performing strongly in the growing PSMA-PET imaging market Revenue from U.S. sales of Illuccix (A$M) • Revenue from U.S. sales of Illuccix of $213.5M (US$143.8M) 225 213.5 • Customer mix has evolved, in line with 150 A$M increased presence in
Slide 15: The Illuccix difference
The Illuccix difference Clinical accuracy + optimum scheduling flexibility New scientific publications and guidelines illustrate 68Ga-PSMA-11 PET/CT has validated accuracy compared to other PSMA imaging agents h High true positive rates of Established excellence in Accurate interpretation with high
Slide 16: Illuccix global rollout
Illuccix global rollout Commercialisation and marketing authorisations progressing in major global markets Recent updates: • Europe Middle East and Africa: Marketing Authorisation Application submitted to UK Medicines and Healthcare products Regulatory Agency3; EU submission filed with BfArM Federal
Slide 17: Growth drivers in the PSMA PET imaging market
Growth drivers in the PSMA PET imaging market AUA/SUO 2023 updated guidelines support expanded use of PSMA-PET imaging1 PSMA PET added as preferred imaging method (with or without CT, MRI, Solidifies PSMA Tc bone scan) for “periodic staging” of patients with BCR2 (non-metastatic) PET imaging as afte
Slide 18: PSMA PET imaging market growth drivers
PSMA PET imaging market growth drivers Guidelines and evolving clinical practice and evidence driving market expansion Current indications U.S. Total Addressable Market (TAM) 580,000+ scans 1 Initial staging for suspected metastases (NCCN, AUA) 1 135,0001 2 Suspected recurrence (NCCN, AUA) Current i
Slide 19: The power of 68Ga-PSMA-11 PET imaging
The power of 68Ga-PSMA-11 PET imaging New research and clinical experience is demonstrating potential in new applications POTENTIAL NEW PAT I E N T I M PA C T A P P L I C AT I O N S “Molecular biopsy” active Risk stratification and candidates for active surveillance of localised disease1-3 surveilla
Slide 20: Potential to expand the clinical utility
Potential to expand the clinical utility Guidelines and clinical research highlight potential across the patient journey 1) Current indication: Initial 2) Current indication: 3) Current indication: Current staging prior to definitive therapy Suspected recurrence Selection for RLT1 indication Monitor
Slide 21: Potential in active surveillance / biopsy replacement, AI-enabled
Potential in active surveillance / biopsy replacement, AI-enabled The PRIMARY study using PSMA PET to improve detection of prostate cancer1 Using Intraprostatic 68Ga-PSMA PET/CT patterns to optimise prostate cancer diagnosis and detect clinically significant prostate cancer P R I M A R Y P R I M A R
Slide 22: Working with leading edge technology innovators
Working with leading edge technology innovators Illuccix patient imaged with uEXPLORER® PET CT at BAMF Health Ability to detect lesions <1.5mm Greater throughput of patients 10 second 30 second 120 second 300 second acquisition acquisition acquisition acquisition Note: Representative patient scan. I
Slide 23: Summary: Leadership in urologic oncology
Summary: Leadership in urologic oncology Building deep relationships with the Illuccix® customer Supporting the urologic patient across the continuum of imaging, surgery and therapy h Diagnosis & Staging Surgical Therapy Technologies TLX250-CDx Telix AITM 23
Slide 24: Program highlights
Program highlights €) Telix
Slide 25: Core pipeline: Oncology and rare diseases
Core pipeline: Oncology and rare diseases Prostate PSMA1 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 68Ga Imaging Small molecule TLX591-CDx (68Ga-PSMA-11, Illuccix®) Antibody 177Lu Therapy TLX591 (177Lu-rosopatamab) Kidney CAIX2 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 89Zr Imaging Antibody TLX250-CDx (89Zr-girent
Slide 26: Clinical development highlights
Clinical development highlights Progress across multiple therapeutic trials STARBURST and STARLITE-1 & 2 ZIRDOSE-CP OPALESCENCE CAIX PROGRAM (INCLUDING RENAL CANCER) STARSTRUCK FPI screening patients (China) FPI complete 30 patients dosed in SELECT data ProstACT GLOBAL GLOBAL US IND PROSTATE CANCER
Slide 27: TLX250-CDx: Further data supports expanded utility
TLX250-CDx: Further data supports expanded utility Scale-up underway to support regulatory filing and commercial launch • Type B meeting with U.S. Food and Drug Administration (FDA) • Regulatory submission underway • First sites on-boarded in European Early Access program, expanded access program be
Slide 28: ProstACT SELECT study: Enrolment complete
ProstACT SELECT study: Enrolment complete Correlation between imaging and therapy to optimise patient selection • Study purpose : Multi-centre study comparing 68Ga-PSMA and STUDY DESIGN 177Lu-PSMA, specifically confirming the similarity of small 30 patients dosed molecule and antibody-based targeti
Slide 29: “SELECT” Example
“SELECT” Example Demonstrates therapeutic potential of TLX591 Key observations • Preliminary data show sufficient uptake and retention in tumour and metastases up to 14 days post-injection • Long retention period in the tumour (and metastases) maximised cell-killing effect of the 177Lu radioisotope
Slide 30: Recent and upcoming milestones
Recent and upcoming milestones Illuccix® - ProstACT Four key continued GLOBAL patient NDA for brain recruitment and BLA submission cancer imaging catalysts revenue growth for TLX250-CDx and global data readout (TLX101-CDx) rollout ProstACT SELECT EXPECTED MILESTONES 2023 H1 2023 Achievements Illucci
Slide 31: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com 31
Telix Pharmaceuticals — H1 2023 Earnings Presentation on 6ix